Product Description

ENASINIB 50 Tablet contains Enasidenib 50 mg, a targeted anticancer medicine. It is an isocitrate dehydrogenase 2 inhibitor used for the treatment of certain types of acute myeloid leukemia with a susceptible IDH2 mutation. Treatment should be initiated and monitored by a qualified oncology specialist.

🔹 Key Uses
Treatment of relapsed or refractory acute myeloid leukemia with a susceptible IDH2 mutation
Used in patients whose leukemia has returned or has not responded adequately to previous treatment

🔹 Composition
Enasidenib 50 mg

🔹 How It Works
Enasidenib selectively inhibits the mutant IDH2 enzyme. Certain IDH2 mutations can cause abnormal production of a metabolite that interferes with normal blood cell development. By inhibiting the mutant enzyme, enasidenib helps reduce this abnormal activity and may promote differentiation of abnormal blood cells.

🔹 Key Benefits
Provides targeted treatment for selected IDH2 mutated acute myeloid leukemia
Helps inhibit abnormal IDH2 enzyme activity
May help control leukemia cells in relapsed or refractory disease

🔹 Dosage and Administration
The dose and duration of treatment must be determined by the oncology specialist based on the patients condition and treatment response. ENASINIB 50 Tablet should be taken exactly as prescribed and swallowed whole with water. It may be taken with or without food, but should be taken consistently in relation to meals.

🔹 Possible Side Effects
Nausea
Vomiting
Diarrhea
Decreased appetite
Fatigue
Shortness of breath
Swelling
Increased bilirubin levels
Low blood cell counts
Tumor lysis syndrome
Differentiation syndrome

🔹 Precautions and Warnings
ENASINIB 50 Tablet should be used only under the supervision of a qualified oncology specialist.
Enasidenib can cause differentiation syndrome, which may be serious or life threatening. Seek immediate medical attention for fever, cough, shortness of breath, rapid weight gain, swelling, low blood pressure, kidney problems, or unexplained fluid accumulation.
Regular blood tests and liver function monitoring may be required during treatment.
Inform the doctor about all medicines, supplements, and herbal products being used because enasidenib can interact with other medicines.
Inform the doctor about pregnancy or plans to become pregnant. Effective contraception should be discussed with the doctor during treatment.
Breastfeeding should be avoided during treatment and for the recommended period after the last dose as advised by the specialist.